instmctions): The purpose of the proposed Mayo Clinic Ovarian SPORE is to sfimulate and facilitate rigorous translational research in ovarian cancer?work that will take new basic and population science discoveries and convert them to improved intervenfions for women with ovarian cancer. Three of the four projects in this SPORE grant rely heavily on this proposed Animal Models Core for the evaluafion of novel interventions (imaging and therapeufics) and for refining experimental approaches and delivery regimens in ovarian cancer-bearing mice. To ensure that all the animal experimentafion can be performed in an expert and efficient manner?, and that SPORE investigators use standarized models for their varying therapeutic strategies?the Animal Core will serve as a central resource and, in collaboration with the laboratory personnel from each project, will perform all the animal experimentafion described in the projects. Specifically, the Animal Core will: (1) ensure the efficient planning, piurchase and ufilizafion of experimental mice, (2) provide the necessary facilifies and animal handling expertise for the projects;(3) provide xenograft and immunocompetent mouse models for testing of novel agents and therapeutic strategies and (4) provide veterinary expertise and access to non-invasive imaging strategies to monitor tumor burden. Importantly, the Animal Models Core will assure the following: (1) Consistency in animal modeling. Modeling through this core will maintain consistency in methods and outcomes, making it easier to reproduce our findings and easier to combine approaches from other labs;(2) Provision of strong animal modeling expertise to all projects. While all project teams have had experience with animal models, some have less than others. By providing a core, we can ensure that all SPORE members will have access to the highest level of skills available;(3) Opfimal interaction across projects with regard to modeling strategies. The core will bring together the investigators from each project and provide an outstanding avenue for new collaborations and the strengthening of existing collaborafions; (4) Efficiency in animal use and care. This core will result in an organized approach to animal use, minimizing waste and the numbers of animals used and eliminafing redundancy in personnel.
The Animal Models core will develop and maintain murine models of ovarian cancer. These models are necessary for understanding the complex interacfions of ovarian cancer with normal healthy tissues and the immune system. Further, the models are needed for the development of novel therapeutics that require animal tesfing prior to human clinical use.
|Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025|
|Zhang, Qing; Wang, Chen; Cliby, William A (2018) Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer. Gynecol Oncol :|
|Morehead, Lauren C; Cannon, Martin J (2018) Further clinical advancement of dendritic cell vaccination against ovarian cancer. Ann Res Hosp 2:|
|Botuyan, Maria Victoria; Cui, Gaofeng; Drané, Pascal et al. (2018) Mechanism of 53BP1 activity regulation by RNA-binding TIRR and a designer protein. Nat Struct Mol Biol 25:591-600|
|Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320|
|Earp, Madalene; Tyrer, Jonathan P; Winham, Stacey J et al. (2018) Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS One 13:e0197561|
|O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166|
|Wu, Chenming; Luo, Kuntian; Zhao, Fei et al. (2018) USP20 positively regulates tumorigenesis and chemoresistance through ?-catenin stabilization. Cell Death Differ 25:1855-1869|
|Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2018) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18:177-187|
|Li, Lei; Liu, Tongzheng; Li, Yunhui et al. (2018) The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization. Oncogene 37:2422-2431|
Showing the most recent 10 out of 294 publications